Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations.~* Must have a diagnosis of primary-progressive, secondary-progressive, progressive-remitting, or relapsing-remitting multiple sclerosis (MS) per revised McDonald Committee criteria (\[Polman et al, 2011\]) as defined by Lublin and Reingold \[Lublin and Reingold 1996\] of at least 3 months duration.~* Have a walking impairment as determined by the Investigator.~* Able to perform the Timed 25-foot Walk Test with or without a walking aid.~* Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.~* Able to understand and comply with the requirements of the protocol.~Key Exclusion Criteria:~* Known allergy to pyridine-containing substances or to any of the inactive ingredients in the prolonged-release fampridine tablet.~* Any history of seizure, epilepsy, or other convulsive disorder, with the exception of febrile seizures in childhood.~* An estimated creatinine clearance of \<80 mL/minute.~* Subject needs to take medicinal products that are inhibitors of organic cation transporter 2 (OCT2 \[e.g., cimetidine\]).~* Female subjects who are currently pregnant or who are considering becoming pregnant while participating in the study.~* Female subjects who are currently breastfeeding.~* Previous exposure to fampridine.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- (BIIB041) Fampridine (Type: EXPERIMENTAL): All participants take 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, a participant continues 10 mg fampridine twice daily for 44 weeks. Treatment non-responders can continue without treatment by completing quality of life questionnaires.

Based on this trial design, predict the completion outcome and termination type (if applicable).